IGM Biosciences is a biotech company that develops Immunoglobulin M (IgM) antibodies for various diseases and cancers. Their lead product IGM-2323 is currently in Phase 2 clinical trials to treat relapsed/refractory B cell Non-Hodgkin's lymphoma (NHL). IGM Biosciences has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies.